- After the failure of two development programs in 2020, Ironwood Pharmaceuticals, Inc. is without a clinical asset.
- The recent departure of the company’s CEO after the promotion of activist investor Alex Denner to its board has the investment community speculating that a sale is in the offing.
- With its Linzess franchise generating solid cash flow, a recent headcount reduction, and a beneficial owner adding to his 13D position, Ironwood merited a deeper dive.
- A full investment analysis is provided below.
For further details see:
Taking A Look Inside At Ironwood